← Back to all trials
Recruiting
NCT06388967
Pancreatic Cancer Detection Consortium
Conditions: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Stage I, Pancreatic Cancer Stage, Pancreatic Cancer Resectable, Pancreatic Cancer Stage 0, Pancreatic Cancer Stage II, Pancreatic Cancer Stage III, Pancreatic Cancer, Adult, Pancreatic Cancer Non-resectable
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Enrollment: 2000
Sponsor: City of Hope Medical Center
Location: Translational Genomics Research Institute Phoenix Arizona
Summary
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Eligibility Criteria
Inclusion Criteria:
* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)
Exclusion Criteria:
* Lack of written informed consent.
Source: ClinicalTrials.gov (NCT06388967). StuddyBuddy aggregates publicly available trial information.
